Cathie Wood Still Interested In Psychedelics, She Bought Over 3 Million Atai Shares In July Alone

Comments
Loading...

Several weeks ago, Cathie Wood's ARK Fund ARKG invested in the biotech psychedelics sector, specifically in major player Atai Life Sciences ATAI.  

The first purchase took place in February 2022, when ARK bought 83,278 shares of Atai Life Sciences. Less than two weeks later, the company acquired four times that, bringing its total ownership to over 340,000 shares, as first reported by Jason Najum on Microdose.

In early July 2022, the company’s spreadsheet showed it held a total 1,827,047 of Atai’s shares -representing an increase of more than 138,000 shares from March 2022. 

By mid-July, the total monthly investment was 621,812 shares. Yet ARK further acquired shares. Now it can be said that the total purchase of Atai stock for that month is over 3 million (3,018,751). 

Considering its rounding $4 for July, that’s $12 million invested in psychedelics by Cathie Wood’s fund, aka a noteworthy purchase from a celebrity investor

Photo Courtesy of Jeffrey Blum on Unsplash.

Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.